Vivanza Biosciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Net Income	-6.74	5.47	5.98	3.33	0.75
Depreciation & Amortization	0.14	0.12	0.03	0.07	0.1
Other Operating Activities	3.53	4.12	4.19	4.05	4.67
Change in Accounts Receivable	34.8	9.4	-46.39	-15.9	2.88
Change in Inventory	-2.57	4.68	-0.47	-17.75	3.13
Change in Accounts Payable	-56.17	-13.15	40.64	16.2	-42.78
Change in Other Net Operating Assets	2.02	9.79	-13.44	34.66	3.59
Operating Cash Flow	-24.99	20.44	-9.46	24.67	-27.64
Capital Expenditures	-0.08	-0.38	-	-	-0.21
Investing Cash Flow	-0.08	-0.38	-	-	-0.21
Short-Term Debt Issued	-	-	-	-	1.82
Long-Term Debt Issued	28.3	-	36.53	-	-
Total Debt Issued	28.3	-	36.53	-	1.82
Long-Term Debt Repaid	-	-40.77	-	-6.04	-2.13
Total Debt Repaid	-	-40.77	-	-6.04	-2.13
Net Debt Issued (Repaid)	28.3	-40.77	36.53	-6.04	-0.3
Other Financing Activities	-3.73	20.96	-26.21	-18.73	25
Financing Cash Flow	24.57	-19.8	10.32	-24.77	24.7
Miscellaneous Cash Flow Adjustments	-0	-	-	-	0
Net Cash Flow	-0.5	0.26	0.86	-0.1	-3.16
Free Cash Flow	-25.07	20.06	-9.46	24.67	-27.86
Free Cash Flow Margin	-33.55%	7.19%	-5.21%	22.03%	-28.02%
Free Cash Flow Per Share	-0.63	0.51	-0.24	0.62	-0.70
Cash Interest Paid	3.51	4.13	4.19	4.06	4.68
Cash Income Tax Paid	0.07	1.49	1.18	0.01	0.48
Levered Free Cash Flow	-29.53	35.53	-27.11	-23.72	-2.76
Unlevered Free Cash Flow	-27.34	38.11	-24.49	-21.19	0.16
Change in Working Capital	-21.92	10.73	-19.65	17.22	-33.17

Source: S&P Global Market Intelligence. Standard template. Financial Sources.